<DOC>
	<DOCNO>NCT01228513</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety three concentration development drug compare placebo treatment atopic dermatitis .</brief_summary>
	<brief_title>Efficacy Safety Different Concentrations ZK245186 Atopic Dermatitis ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Diagnosis atopic dermatitis accord Hanifin Rajka criterion Body surface area affect atopic dermatitis le 15 % start treatment Pregnancy breastfeed Conditions may pose threat patient effect outcome study Widespread atopic dermatitis ( AD ) require systemic treatment Immunocompromized condition At least 2 week local AD treatment treatment systemic antibiotic At least 1 month systemic AD treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>